2024
Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography
Okamoto M, Yamaguchi S, Sawaya R, Echizenya S, Ishi Y, Kaneko S, Motegi H, Toyonaga T, Hirata K, Fujimura M. Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of 18F‐Fluoromisonidazole and 18F‐Fluorodeoxyglucose Positron Emission Tomography. BioMed Research International 2024, 2024: 2973407. PMID: 38449509, PMCID: PMC10917478, DOI: 10.1155/2024/2973407.Peer-Reviewed Original ResearchMeSH KeywordsFluorine RadioisotopesFluorodeoxyglucose F18GlioblastomaGlucoseGlucose-6-PhosphataseHumansHypoxiaMisonidazolePositron-Emission TomographyRNA, MessengerTomography, X-Ray ComputedConceptsPositron emission tomographyF-FDGMRNA expressionOverall survivalGlucose metabolismF-FDG positron emission tomographyAssociated with poor overall survivalProtein expressionEmission tomographyGross total resectionPotential key moleculesFluorine-18 fluorodeoxyglucoseHypoxic conditionsDegree of glucose metabolismMolecular mechanisms of glucose metabolismAggressive primary brain tumorPoor overall survivalPrimary brain tumorKey moleculesTotal resectionPreoperative examinationIntratumoral hypoxiaPrognostic valuePoor prognosisBiomarkers of glioblastoma
2023
Markerless head motion tracking and event-by-event correction in brain PET
Zeng T, Lu Y, Jiang W, Zheng J, Zhang J, Gravel P, Wan Q, Fontaine K, Mulnix T, Jiang Y, Yang Z, Revilla E, Naganawa M, Toyonaga T, Henry S, Zhang X, Cao T, Hu L, Carson R. Markerless head motion tracking and event-by-event correction in brain PET. Physics In Medicine And Biology 2023, 68: 245019. PMID: 37983915, PMCID: PMC10713921, DOI: 10.1088/1361-6560/ad0e37.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsBrainHeadHumansImage Processing, Computer-AssistedMotionMovementPhantoms, ImagingPositron-Emission TomographyConceptsPoint source studyHead motion correctionSmaller residual displacementMotion correctionIterative closest point (ICP) registration algorithmHead motion trackingSpatial resolutionResidual displacementData-driven evaluation methodHigh spatial resolutionLow noiseMotion trackingStereovision cameraMotion tracking deviceStructured lightEvent correctionBrain positron emission tomography (PET) imagingTracking deviceReconstruction resultsHMT methodPoint cloudsNegative biasReference cloudUMTEvaluation methodDose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networks
Li A, Yang B, Naganawa M, Fontaine K, Toyonaga T, Carson R, Tang J. Dose reduction in dynamic synaptic vesicle glycoprotein 2A PET imaging using artificial neural networks. Physics In Medicine And Biology 2023, 68: 245006. PMID: 37857316, PMCID: PMC10739622, DOI: 10.1088/1361-6560/ad0535.Peer-Reviewed Original ResearchMeSH KeywordsBrainDrug TaperingGlycoproteinsHumansImage Processing, Computer-AssistedNeural Networks, ComputerPositron-Emission TomographySynaptic VesiclesPrincipal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease
O'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAmyloidAmyloidogenic ProteinsBrainCognitive DysfunctionHumansPositron-Emission TomographyPrincipal Component AnalysisConceptsCognitive domainsCognitive performanceSubjects' scoresCortical regionsNeuropsychological batteryEarly Alzheimer's diseaseAD groupBilateral regionsNormal participantsNegative loadingsCognitive impairmentCN participantsAlzheimer's diseaseParticipantsStructural correlatesStrong contributionParticipant characteristicsScoresPositive loadingsData-driven approachTotal variancePrincipal component analysisSpecific spatial patternsPreclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates
Chen B, Ojha D, Toyonaga T, Tong J, Pracitto R, Thomas M, Liu M, Kapinos M, Zhang L, Zheng M, Holden D, Fowles K, Ropchan J, Nabulsi N, De Feyter H, Carson R, Huang Y, Cai Z. Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 50: 2081-2099. PMID: 36849748, DOI: 10.1007/s00259-023-06162-y.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrainGlioblastomaPoly(ADP-ribose) Polymerase InhibitorsPositron-Emission TomographyPrimatesRatsTissue DistributionConceptsPositron emission tomographyHealthy nonhuman primatesVolume of distributionDistribution volume ratioBrain kineticsRat glioblastoma modelPreclinical evaluationBrain regionsGlioblastoma modelPET tracersNonhuman primatesTumor-bearing ratsEx vivo biodistributionPET imaging resultsActive clinical trialsTreatment of glioblastomaHigh specific uptakeDynamic PET scansNoninvasive quantificationBrain positron emission tomographyNondisplaceable volumeBrain penetrationLow nonspecific uptakePrognostic informationClinical trialsDeep learning-based attenuation map generation with simultaneously reconstructed PET activity and attenuation and low-dose application
Shi L, Zhang J, Toyonaga T, Shao D, Onofrey J, Lu Y. Deep learning-based attenuation map generation with simultaneously reconstructed PET activity and attenuation and low-dose application. Physics In Medicine And Biology 2023, 68: 035014. PMID: 36584395, DOI: 10.1088/1361-6560/acaf49.Peer-Reviewed Original Research
2022
Deep learning–based attenuation correction for whole-body PET — a multi-tracer study with 18F-FDG, 68 Ga-DOTATATE, and 18F-Fluciclovine
Toyonaga T, Shao D, Shi L, Zhang J, Revilla EM, Menard D, Ankrah J, Hirata K, Chen MK, Onofrey JA, Lu Y. Deep learning–based attenuation correction for whole-body PET — a multi-tracer study with 18F-FDG, 68 Ga-DOTATATE, and 18F-Fluciclovine. European Journal Of Nuclear Medicine And Molecular Imaging 2022, 49: 3086-3097. PMID: 35277742, PMCID: PMC10725742, DOI: 10.1007/s00259-022-05748-2.Peer-Reviewed Original ResearchConceptsNeural networkNovel deep learningNet neural networkPET/CT datasetsImage analysis metricsPhysics-based loss functionDeep learningCT-derived attenuation mapAttenuation mapLoss functionAnalysis metricsDetail recoveryTumor volume estimationMLAACT datasetsOSEM algorithmNetworkAlgorithmAttenuation correctionCorrection framework
2021
Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease
Lu Y, Toyonaga T, Naganawa M, Gallezot JD, Chen MK, Mecca AP, van Dyck CH, Carson RE. Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease. NeuroImage 2021, 238: 118248. PMID: 34119639, PMCID: PMC8454285, DOI: 10.1016/j.neuroimage.2021.118248.Peer-Reviewed Original ResearchAlzheimer DiseaseBrainCerebrovascular CirculationHumansImage Processing, Computer-AssistedPositron-Emission TomographyRadiopharmaceuticals
2020
Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study
Finnema SJ, Toyonaga T, Detyniecki K, Chen M, Dias M, Wang Q, Lin S, Naganawa M, Gallezot J, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study. Epilepsia 2020, 61: 2183-2193. PMID: 32944949, DOI: 10.1111/epi.16653.Peer-Reviewed Original ResearchConceptsMedial temporal lobe sclerosisTemporal lobe epilepsyTLE subjectsPositron emission tomographyLobe epilepsyJ BPSynaptic vesicle protein 2APartial volume correctionTemporal lobe sclerosisPositron emission tomography studyEmission tomography studiesSeizure onset zonePromising biomarker approachJ bindingPresurgical selectionSclerotic hippocampusHippocampal asymmetryTLE patientsRegional binding patternsControl subjectsCentrum semiovaleContralateral regionsEpilepsy patientsOutcome measuresOnset zone
2019
In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease
Toyonaga T, Smith LM, Finnema SJ, Gallezot JD, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y, Strittmatter SM, Carson RE. In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. Journal Of Nuclear Medicine 2019, 60: 1780-1786. PMID: 31101744, PMCID: PMC6894376, DOI: 10.2967/jnumed.118.223867.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAnimalsBenzodioxolesDisease Models, AnimalFemaleKineticsMaleMicePositron-Emission TomographyPyridinesPyrrolidinesPyrrolidinonesQuinazolinesSynapsesConceptsAPP/PS1 micePS1 miceAlzheimer's diseaseWT miceSynaptic densityC-UCBDrug washoutTreatment effectsPresenilin 1 (PS1) double transgenic miceHippocampal synaptic densityAPP/PS1Double transgenic miceEnd of treatmentWild-type miceAmyloid precursor proteinEarly Alzheimer's diseaseSignificant differencesSUVR-1New PET tracersMild cognitive impairmentAD miceSynaptic deficitsOral gavageAD treatmentHealthy subjects
2017
Players of ‘hypoxia orchestra’ – what is the role of FMISO?
Toyonaga T, Hirata K, Shiga T, Nagara T. Players of ‘hypoxia orchestra’ – what is the role of FMISO? European Journal Of Nuclear Medicine And Molecular Imaging 2017, 44: 1679-1681. PMID: 28634683, DOI: 10.1007/s00259-017-3754-9.Commentaries, Editorials and Letters
2016
18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
Toyonaga T, Hirata K, Yamaguchi S, Hatanaka KC, Yuzawa S, Manabe O, Kobayashi K, Watanabe S, Shiga T, Terasaka S, Kobayashi H, Kuge Y, Tamaki N. 18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. European Journal Of Nuclear Medicine And Molecular Imaging 2016, 43: 1469-1476. PMID: 26841941, DOI: 10.1007/s00259-016-3320-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrain NeoplasmsCerebellumFemaleHumansMaleMiddle AgedMisonidazoleNecrosisPositron-Emission TomographyConceptsPresence of necrosisBrain tumorsFMISO PETFMISO uptakeSevere hypoxiaFMISO PET/Brain tumor patientsPositron emission tomography (PET) tracerPositron emission tomographyEmission tomography tracerHistopathological necrosisPathological necrosisPoor prognosisSurgical strategyIntratumoral necrosisNeuroepithelial tumorsTumor resectionPathological diagnosisTumor patientsCerebellum ratioTreatment decisionsMethodsThis studyGroup 2Group 1Experienced neuropathologist